Amyloid aggregation may be a feature, not a bug, of the protein’s function. A bug-catching feature.
A single injection of the peptide hormone fibroblast growth factor 1 (FGF1) directly into the brain induced long-term remission from type 2 diabetes in rats and mice.
Despite a few FDA qualms, EMDAC embraced a fixed combination diabetes drug that couples a titratable basal insulin product with a GLP-1 receptor agonist that has only a few recommended effective doses.more »
- Astrazeneca’s pain is Relypsa’s gain as FDA stings HK drug ZS-9 with CRL
- Industry warns of high cost to U.K. biopharma as Brexit vote looms
- Of D-dimers, NDA timers: Portola’s betrixaban push targets second-half filing
- Amyloid plaques ‘entomb’ microbes as immune defense
- PMI data security policies are starting to take ...
- China cuts Astrazeneca, Glaxosmithkline and Betta drug prices as part of medical reform
- China’s ICT comes out of stealth with CAR T trial results in leukemia
- BD pharma execs make pitches; VC money sits as valuations climb
- China gets ready for immunotherapy future despite uncertainty
- Better regs, cross-border deals strengthen China...
Several interesting ongoing story lines reignited investors' interest in biotech during the month and helped halt the slide in the sector's valuation. Biopharma M&A is always an attention-grabber and Sanofi SA's hostile $9 billion-plus bid for Medivation Inc. provided that, with the latest chapter seeing the pharma seeking to oust the Medivation board and replace it with its own slate of candidates. There has also been an intriguing subplot with Amgen Inc., Celgene Corp. and Gilead Sciences Inc. all rumored to be contemplating their own bids for Medivation.
Findings that precision medicine benefits patients even in phase I trials, and patients treated with Keytruda (pembrolizumab, Merck & Co. Inc.) had a three-year survival rate of about 40 percent, were among the highlights of the sprawling treasure trove that is the American Society of Clinical Oncology's (ASCO) annual meeting abstracts. Abstracts for the 2016 annual meeting, which will be held in Chicago June 3-7, were publicly released yesterday.READ MORE »
- Study identifies breast cancer’s traffic signals to bone »
- Combination may induce necroptosis to treat AML »
- Soil bacterium protects from inflammation, stress effects »
- Viral adaptation favors HIV, predicts disease course »
- Cancer drug stimulates stem cells, wound healing »
- Hormone increases fat absorption, obesity risk »
- Cheap, quick platform technology leads to cheap, quick Zika diagnostic »
- New therapeutic target identified against glioblastoma »
- Study identifies new therapeutic target for AMD »
- An end to Charlotte’s web?May 10, 2016 | 9:09 PM | Posted by: Mari Serebrov
- Building a wall to keep companies inApril 05, 2016 | 9:10 PM | Posted by: Mari Serebrov
- Ignoring the science for a bigger box of crayonsMarch 08, 2016 | 9:58 PM | Posted by: Mari Serebrov
- Shkreli: A supervillain with a dastardly plan? Or a distraction from the real problem? February 09, 2016 | 2:40 PM | Posted by: Jennifer Boggs
- No joy in Bio-villeDecember 30, 2015 | 10:48 PM | Posted by: Mari Serebrov
Partners in Focus
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter